Form 4: Verve Therapeutics CFO Reports Equity Conversion Following Eli Lilly Merger Completion

Verve Therapeutics' Chief Financial Officer, Allison Dorval, reported the conversion of her equity holdings into cash and contingent value rights following the company's acquisition by Eli Lilly and Company.

Summary

• The merger of Verve Therapeutics, Inc. with Ridgeway Acquisition Corporation, an indirect wholly owned subsidiary of Eli Lilly and Company, became effective on July 25, 2025.
• Verve Therapeutics is now a wholly owned subsidiary of Eli Lilly and Company.
• Shareholders received $10.50 per share in cash plus one non-tradable contingent value right (CVR) for each share.
• Each CVR represents a contractual right to receive up to $3.00 in cash upon the achievement of a specified business milestone.
• Outstanding stock options with an exercise price less than $10.50 were cancelled, with holders receiving cash equal to ($10.50 exercise price) multiplied by the number of shares, plus one CVR per share.
• Unvested Restricted Stock Units (RSUs) were cancelled, with holders receiving cash equal to $10.50 multiplied by the number of shares, plus one CVR per RSU.
• Stock options with an exercise price equal to or greater than $10.50 but less than $10.50 plus the $3.00 milestone payment were cancelled, with holders entitled to receive a cash payment equal to the CVR payment multiplied by the number of shares, provided the sum of cash consideration and milestone payment exceeds the exercise price.
• Allison Dorval, Chief Financial Officer, disposed of 13,280 shares of common stock and various stock options and restricted stock units as part of the merger.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, providing liquidity and potential future upside (via CVRs) to shareholders and equity holders. While the company loses its independent status, the transaction appears to have proceeded as planned, offering a clear exit for investors.

Positives

• Shareholders received a cash consideration of $10.50 per share.
• Shareholders also received a Contingent Value Right (CVR) potentially worth up to an additional $3.00 per CVR, offering upside potential based on a future milestone.
• Equity awards (stock options and RSUs) were converted into cash and CVRs, providing liquidity and potential future value to equity holders.

Negatives

• Verve Therapeutics ceased to be an independent publicly traded entity, becoming a wholly owned subsidiary of Eli Lilly and Company.
• Existing equity awards were cancelled, albeit converted into cash and CVRs, ending direct equity participation in Verve Therapeutics.
• The CVR payment is contingent on the achievement of a specific milestone, introducing uncertainty regarding the full $3.00 per CVR payment.

Risks

• The Contingent Value Right (CVR) payment of up to $3.00 is dependent on the achievement of a specific milestone, meaning the full value is not guaranteed.
• Holders of certain stock options (Closing Date Contingent Options) will only receive a payment if the sum of the Cash Consideration and the Milestone Payment exceeds their exercise price, and only when CVR payments are made.

Future Outlook

The future outlook for former Verve Therapeutics shareholders includes the potential to receive an additional cash payment of up to $3.00 per Contingent Value Right (CVR) upon the achievement of a specific business milestone.

Industry Context

This acquisition reflects a broader trend in the biotechnology and pharmaceutical industries where larger established companies acquire smaller, innovative firms to expand their pipelines and intellectual property. Such mergers often provide an exit strategy for early investors and liquidity for employees with equity stakes, while the acquiring company gains access to promising new therapies or technologies.

Comparison to Industry Standards

• The structure of the acquisition, involving a cash component and a Contingent Value Right (CVR), is a common mechanism in biotech M&A, particularly when the acquired company's assets are still in development or require further milestones to be met. This allows the acquirer to mitigate risk while providing potential upside to the acquired company's shareholders.
• Comparable deals often include similar CVR structures, such as the acquisition of MyoKardia by Bristol Myers Squibb, where a CVR was tied to the approval of mavacamten, or the acquisition of Acceleron Pharma by Merck, which included a CVR for a pulmonary hypertension drug.
• The per-share cash consideration of $10.50, combined with a potential $3.00 CVR, provides a total potential value of $13.50 per share, which would be evaluated against Verve Therapeutics' pre-announcement stock price and analyst price targets to assess the premium offered.

Related Party Transactions

• The merger itself can be considered a transaction involving related parties (the company and its officers/directors who held equity), as their equity was converted as part of the deal.

Stakeholder Impact

• Shareholders: Received cash consideration and CVRs, providing liquidity and potential future value, but lost direct equity ownership in an independent Verve Therapeutics.
• Employees (with equity): Equity awards were converted to cash and CVRs, providing financial benefit, but their employment status and future compensation structure under Eli Lilly are not detailed here.
• Company (Verve Therapeutics): Ceased to be an independent entity and became a wholly owned subsidiary of Eli Lilly, integrating its operations and pipeline into a larger pharmaceutical company.

Next Steps

• Achievement of the specified milestone for the Contingent Value Right (CVR) payment.
• Payment of up to $3.00 per CVR to eligible holders upon milestone achievement.
• Payment of contingent cash amounts to holders of certain stock options (Closing Date Contingent Options) upon CVR payments.

Key Dates

Keywords

Verve Therapeutics, Eli Lilly, Merger, Acquisition, SEC Form 4, Insider Trading, Equity Conversion, Contingent Value Right, CVR, Stock Options, Restricted Stock Units, Biotechnology, Pharmaceuticals